- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02245776
Stem Cell Therapy in Incurable Neurological Disorders
October 23, 2018 updated by: Neurogen Brain and Spine Institute
Autologous Bone Marrow Mononuclear Cell Therapy for Incurable Neurological Disorders
The purpose of the study was to analyze the benefit of autologous mononuclear cell therapy in incurable neurological disorders.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maharashtra
-
Navi Mumbai, Maharashtra, India, 400706
- Neurogen brain and spine institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 80 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- diagnosed cases of incurable neurological disorders
- age above 6 months
Exclusion Criteria:
- presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/Hepatitis C Virus
- malignancies
- bleeding tendencies
- pneumonia
- renal failure
- severe liver dysfunction
- severe anemia [Hemoglobin < 8]
- any bone marrow disorder
- space occupying lesion in brain
- other acute medical conditions such as respiratory infection and pyrexia
- pregnancy
- lactation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Stem Cell
Bone marrow mononuclear cell transplantation
|
Intrathecal autologous bone marrow mononuclear cell transplantation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in various clinical symptoms of neurological disorders
Time Frame: 1 year
|
Change in various symptoms such as muscle strength, limb strength, ambulation, neck holding, bladder bowel management, spasticity, sensation, speech, etc depending on the disorder will be recorded at 1 year follow up.
Percentage analysis of each symptom will be carried out to study the benefits of stem cell therapy on them.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2008
Primary Completion (Anticipated)
June 1, 2018
Study Completion (Anticipated)
December 1, 2018
Study Registration Dates
First Submitted
September 12, 2014
First Submitted That Met QC Criteria
September 17, 2014
First Posted (Estimate)
September 22, 2014
Study Record Updates
Last Update Posted (Actual)
October 25, 2018
Last Update Submitted That Met QC Criteria
October 23, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NGBSI-16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurological; Disorder, Nervous System
-
Forest Hills LabLiberyxCompletedNeurological DisorderUnited States
-
Pôle Saint HélierINSA RennesCompleted
-
Pôle Saint HélierINSA RennesCompletedNeurological DisorderFrance
-
National Institute of Neurological Disorders and...CompletedNeurological DisorderUnited States
-
Riphah International UniversityRecruitingNeurological DisorderPakistan
-
University Hospital, ToulouseCompleted
-
Wayne State UniversityCompletedNeurological Disorder | Healthy ControlUnited States
-
Massachusetts General HospitalCompletedIntensive Care Neurological DisorderUnited States
-
University of LeedsThe Royal College of Surgeons of EnglandCompletedSurgery | Surgery--Complications | Outcome, Fatal | Neurological Disorder | Morality | Neurological Morbidity | Neurological Complication | Comorbidities and Coexisting Conditions | Neurological Diseases or Conditions | Neurological Procedural Complication
-
University College, LondonRecruitingNeurological Disorder | Ultrasound | Vocal Fold MovementUnited Kingdom
Clinical Trials on Stem Cell
-
China Medical University HospitalUnknownIschemia | Ischemic Stroke | Brain Ischemia | Infarction, Middle Cerebral Artery | Ischaemic Cerebral InfarctionTaiwan
-
National Heart Institute, MexicoNational Center of Blood Transfusion Mexico.UnknownAcute Myocardial InfarctionMexico
-
Royan InstituteCompletedOsteoarthritisIran, Islamic Republic of
-
Northwestern UniversityTerminated
-
Mongolian National University of Medical SciencesNot yet recruiting
-
Hackensack Meridian HealthActive, not recruitingDiabetes Mellitus Type 1United States
-
Royan InstituteCompletedCerebral PalsyIran, Islamic Republic of
-
Al-Azhar UniversityCompletedPremature Ovarian FailureEgypt
-
Mayo ClinicUniversity of Alabama at Birmingham; University of Mississippi Medical CenterCompletedChronic Kidney Disease | Renal Artery Stenosis | Ischemic Nephropathy | Renovascular DiseaseUnited States
-
Royan InstituteCompletedOsteoarthritisIran, Islamic Republic of